Page last updated: 2024-08-23

cabergoline and Minimal Disease, Residual

cabergoline has been researched along with Minimal Disease, Residual in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	2 (40.00)	2.80

Authors

Authors	Studies
Ahn, SS; Kim, D; Kim, EH; Kim, K; Ku, CR; Lee, EJ; Moon, JH; Park, YW	1
Bronstein, MD; Greenman, Y	1
Batista, RL; Cescato, VAS; Cunha-Neto, MB; da Silva, GO; Herkenhoff, CGB; Medeiros, RSS; Musolino, NRC; Trarbach, EB	1
Ahmad, MS; Nakhleh, A; Pearl, IW; Reut, M; Saiegh, L; Shechner, C	1
Buchfelder, M; Harms, E; Hüfner, M; Saeger, W; Siggelkow, H	1

Trials

1 trial(s) available for cabergoline and Minimal Disease, Residual

Article	Year
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. American journal of clinical oncology, 2019, Volume: 42, Issue:2 Topics: Adenoma; Antiparkinson Agents; Cabergoline; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Pituitary Neoplasms; Prognosis; Receptors, Dopamine D2; Survival Rate	2019

Article

Year

Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.

American journal of clinical oncology, 2019, Volume: 42, Issue:2

Topics: Adenoma; Antiparkinson Agents; Cabergoline; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Pituitary Neoplasms; Prognosis; Receptors, Dopamine D2; Survival Rate

2019

Other Studies

4 other study(ies) available for cabergoline and Minimal Disease, Residual

Article	Year
Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma. The Journal of clinical endocrinology and metabolism, 2021, 01-23, Volume: 106, Issue:2 Topics: Adolescent; Adult; Biomarkers, Pharmacological; Biomarkers, Tumor; Cabergoline; Cohort Studies; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary Neoplasms; Prolactinoma; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Withholding Treatment; Young Adult	2021
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. European journal of endocrinology, 2021, Aug-27, Volume: 185, Issue:4 Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden	2021
Cabergoline treatment for recurrent Cushing's disease during pregnancy. Hormones (Athens, Greece), 2016, Volume: 15, Issue:3 Topics: Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Female; Humans; Hydrocortisone; Live Birth; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Remission Induction; Treatment Outcome	2016
[Macroadenoma of the pituitary gland with moderate hyperprolactinaemia]. Deutsche medizinische Wochenschrift (1946), 2003, Mar-28, Volume: 128, Issue:13 Topics: Cabergoline; Diagnosis, Differential; Ergolines; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Pituitary Gland; Pituitary Neoplasms; Postoperative Complications; Prolactinoma	2003